CLINICAL TRIALS PROFILE FOR TRIFLUOPERAZINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for TRIFLUOPERAZINE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01765829 ↗ | Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis | Unknown status | Instituto de Salud Carlos III | Phase 3 | 2012-11-01 | The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria. |
| NCT01765829 ↗ | Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis | Unknown status | Fundación Pública Andaluza Progreso y Salud | Phase 3 | 2012-11-01 | The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria. |
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Canadian Institutes of Health Research (CIHR) | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Drug Safety and Effectiveness Network, Canada | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRIFLUOPERAZINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for TRIFLUOPERAZINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for TRIFLUOPERAZINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for TRIFLUOPERAZINE HYDROCHLORIDE
Sponsor Name
